Proprietary BioPharma Data Assets

Accurate, Validated, Decision-Ready Data at Scale

Comprehensive, historically deep, and continuously refreshed intelligence across the full pharmaceutical value chain.

Proprietary BioPharma Data Assets

Addressing the Biggest
Data Challenge

Accessing accurate, validated, and decision-ready BioPharma data at scale is one of the biggest challenges Critical datasets are fragmented, inconsistently structured, difficult to standardize, and expensive to maintain in-house.

Proscizen’s proprietary biopharma data assets address this challenge by delivering comprehensive, historically deep, and continuously refreshed intelligence across the full pharmaceutical value chain. Each dataset is curated by subject-matter experts, rigorously validated, and structured at granular, machine-readable levels—enabling faster analysis, reducing bias, strengthening deal assessment, and supporting more confident capital allocation and strategic planning.

Smarter Transactions
Benchmark and execute smarter transactions with integrated drug licensing and pharma deals & funding intelligence.
Pipeline Tracking
Track global pipelines, products, and lifecycle milestones using comprehensive drug intelligence.
Manufacturing Optimization
Optimize manufacturing and outsourcing decisions through CDMO Sphere.
Proprietary BioPharma Data Assets

Licensing is one of the most critical value-creation levers in pharma. Proscizen’s Licensing Deals Intelligence significantly reduces the time, cost, and risk involved in asset screening, deal benchmarking, valuation, and negotiation.

Trusted by Pharma Business Development, Licensing, Strategy, and Competitive Intelligence teams, our licensing database delivers over two decades of accurately sourced, standardized, and analysis-ready licensing intelligence, helping teams secure optimal deal outcomes in an increasingly competitive environment.

Scale & Coverage

20+ years of historical drug licensing deals

40+ structured data points per deal, including:

In-licensing / Out-licensing
Payment structures (upfronts, milestones, royalties)
Deal type and scope
Drug attributes
Development and commercialization stage
More…

Continuous real-time updates • Deal tracking by company, asset, therapy area, molecule type, geography and more..

Why Proscizen

Analyst-validated deal summaries and context

Comparable deal analysis and benchmarking

Custom datasets aligned to your deal thesis or portfolio focus

Reduced negotiation risk through historical precedent and valuation clarity

Flexible delivery formats for internal modeling and dashboards

Pharma transactions are complex, multi-layered, and value-sensitive. Proscizen’s Deals & Funding Intelligence simplifies deal research by providing accurately sourced, normalized, and deeply analyzed transaction data, enabling confident strategic, financial, and investment decisions.

Used by Pharma leaders, Investment Banks, Private Equity, Venture Capital firms, and Consulting organizations, this database offers clarity across capital movements, corporate restructuring, and strategic transactions.

Scale & Coverage

Transaction Types Covered:

Mergers & Acquisitions
Spin-outs and Divestments
Venture and Growth Financing
Strategic Partnerships
Grant Funding
IPOs
Commercial and Manufacturing Agreements
More…

Depth of Intelligence:

100+ structured deal data points with detailed breakdowns

20+ years of historical pharma transaction data

Deal rationale and strategic context
Financial metrics and valuation indicators
Comparable deal analysis

Why Proscizen

End-to-end visibility across pharma deal activity

Analyst-driven insights beyond raw deal announcements

Custom deal views aligned to sector, geography, or strategy

Ideal for diligence, benchmarking, and investment screening

Navigate the global drug development ecosystem with confidence. Proscizen's Drug Intelligence database provides a comprehensive, continuously updated view of investigational and marketed drugs worldwide—helping teams track competition, identify opportunities, and evaluate portfolio risks.

Scale & Coverage

10,500+ Innovator Pharma and Biotech companies covered

Coverage across:

Preclinical to marketed drugs
Small molecules, biologics, advanced therapies

Drug and pipeline attributes include:

Development phase
Brand and generic names
Therapeutic area and indication
Drug class and mechanism of action
Route of administration and formulation
More…

Special regulatory designations:

Orphan Drug
Fast Track
Breakthrough Therapy
More…

Why Proscizen

Advanced filtering by molecule type, therapy area, company size, and funding stage

Competitive pipeline benchmarking

Early trend identification across R&D and commercialization

Integrated view with company, licensing, and manufacturing intelligence

Manufacturing decisions directly impact speed, quality, cost, and regulatory success. Proscizen's Drug Manufacturing Intelligence enables Pharma sponsors and CDMOs to navigate the global manufacturing ecosystem with precision and confidence.

Sponsors can identify the most suitable manufacturing partners, while CDMOs gain actionable insights into competitors, clients, and market demand.

Scale & Coverage

Manufacturing intelligence for investigational and marketed drugs

Facility-level insights including:

Manufacturing site locations
In-house vs outsourced production status
Scope of outsourced services
Historical manufacturing relationships

CDMO profiles with:

Capabilities and technologies
Molecule and dosage form focus
Existing pharma relationships
Service offerings and capacity indicators

Why Proscizen

Granular pharma–CDMO relationship mapping

Capability-based CDMO screening

Competitive positioning for CDMOs

Strategic sourcing and proposal optimization for sponsors

Get Started Today

Ready to access validated BioPharma data assets?

Discover how Proscizen's Proprietary BioPharma Data Assets can help your organization make smarter, faster, and more confident decisions.

Talk to Our Team →